Pricing Log in Create free account

Celularity, Inc. (CELU) vs IGC Pharma, Inc. (IGC)

Celularity, Inc. and IGC Pharma, Inc. are both Biotechnology companies. Celularity, Inc. and IGC Pharma, Inc. are of similar size ($23.5M and $22.0M). IGC Pharma, Inc. grew revenue faster over the last twelve months: −17.0% against −58.1%. Celularity, Inc. has the higher net margin (−247.7% vs −836.1%) and the lower return on invested capital (−462.8% vs −90.5%). Across the 17 metrics below, Celularity, Inc. leads on 10 and IGC Pharma, Inc. on 7.

Valuation

Metric CELU IGC Biotechnology median
P/E n/m n/m 10.60
P/S 1.19 18.89 9.40
P/B n/m 3.20 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 3.45 19.31 9.02
Earnings yield (222.37%) (47.37%) (32.88%)
Free cash flow yield (40.93%) (27.39%) (23.13%)

Profitability

Metric CELU IGC Biotechnology median
Gross margin 19.23% 23.89% 68.51%
Operating margin (264.27%) (914.80%) 0.00%
Net margin (247.71%) (836.06%) 0.00%
Free cash flow margin (47.80%) (485.92%) 0.00%
Return on equity 151.53% (126.16%) (51.96%)
Return on assets (42.72%) (94.55%) (46.06%)
Return on invested capital (462.77%) (90.48%) 0.00%

Growth

Metric CELU IGC Biotechnology median
Revenue growth (TTM) (58.14%) (17.03%) 6.76%
EPS growth (last fiscal year) (35.98%) 57.85% 29.88%
Revenue growth, 5-year CAGR 13.21% (20.77%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CELU IGC Biotechnology median
Debt to equity (1.20) 0.13 0.00
Current ratio 0.11 0.42 4.97
Net debt to EBITDA (0.77) 0.04 1.01

Dividend

Metric CELU IGC Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CELU IGC Biotechnology median
Market cap 23.54m 21.95m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack